Ivo Abraham, PhD, RN

Professor of Practice

Ivo Abraham is a professor (part-time) in the Department of Pharmacy Practice. He has also served on the faculty of Case Western Reserve University (Cleveland, Ohio), University of Virginia (Charlottesville, Va.), and (part-time) Katholieke Universiteit Leuven (Leuven, Belgium); and as visiting professor at Universiteit Maastricht (Maastricht, The Netherlands), University of Florida (Gainesville, Fla.), Rijksuniversiteit Groningen (Groningen, The Netherlands), University of Pennsylvania (Philadelphia, Penn.), and Chang Gung University (Kwei-Shan Tao-Yuan, Taiwan).  He has lectured, consulted, and conducted research throughout the Americas, Europe, the Asia-Pacific region, and Africa. Being part-time, he divides his time between the University of Arizona and Matrix45, a biopharmaceutical research and consulting company, where he serves as chief scientist.

For the past decade or so, Dr. Abraham’s research has focused mainly on clinical outcomes and effectiveness research, in particular how variability in (drug-centric) treatment regimens is associated with variability in patient outcomes. However, instead of merely evaluating effectiveness (does the treatment work?), the work of his research group addresses the equally important questions of when does the treatment work (and when not), what influences whether the treatment works, why does the treatment work in some patients but not in others, why does the treatment work with some clinicians but not with others, why is the treatment tolerated by some patients but not by others, and how much of patient outcomes is related to patient vs. clinician or treatment center?  In this process, his group uses a comprehensive framework of treatment patterns and outcomes assessment, vulnerability profiling, hierarchical modeling, (non-)responder analysis, and pharmacovigilance and drawing methodologies and statistical models from other disciplines into biomedical research.  

More recently, frustrated by the abundance of evidence but clinicians’ persistent low adoption of evidence-based guidelines, he and his colleagues started examining how practicing in accordance with evidence-based guidelines is directly associated with patient outcomes.

He has (co-)authored 260+ articles and 60+ chapters, and has (co-)edited 29 books, monographs, and journal issues. Since 1984, his research has been funded by federal funding agencies, foundations, and corporations.   He has served as appointed ad hoc reviewer for the NIH, the NIMH, and the AHRQ. He currently serves as an expert adviser to the Innovative Medicines Initiative, a joint 2 billion euro undertaking of the European Union and the biopharmaceutical industry to stimulate innovation in human therapeutics.

His educational and scientific honors and awards include an Invitational research fellowship from the Japan Society for the Promotion of Science (2007-2008), which he conducted at Hyogo University and Aomori University.

View UA Profile

Education & Post Graduate Training: 

BS, Nursing, Katholieke Hogeschool Leuven (Leuven, Belgium)
MS, Psychiatric-Mental Health Nursing, University of Michigan
PhD, Clinical Research, University of Michigan 

Select Publications


Van Aken E, Favreau M, Ramboer E, et al. "Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)." Clin Ophthalmol. 2020;14:4173-4185. PMCID: PMC7720424  PMID: 33299294
Alamer A, Abraham I. "Mortality in COVID-19 patients treated with ACEIs/ARBs: Re-estimated meta-analysis results following the Mehra et al. retraction." Pharmacol Res. 2020;160:105053. PMCID: PMC7326447  PMID: 32619721
Alkhatib NS, Abraham I. "The six Delta platform for outcome-based contracting for pharmaceuticals." J Med Econ. 2020;23(11):1209-1214. PMID: 32930629
Leys AM, Ramboer E, Favreau M, et al. "Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS Study." Clin Ophthalmol. 2020;14:1473-1481. PMCID: PMC7277576  PMID: 32581505
Alkhatib NS, Ramos K, Erstad B, et al. "Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing." J Med Econ. 2020;23(11):1215-1222. PMID: 32845794
Tompkinson M, Fine K, Gruber D, Abraham I, McBride A. "Perceptions of Health-Care Workers of the Cost and Safety of Oral Oncolytic Agents for Patients: A Survey." J Adv Pract Oncol. 2020;11(4):354-365. PMCID: PMC7863127  PMID: 33604096
Combs D, Edgin JO, Klewer S, et al. "OSA and Neurocognitive Impairment in Children With Congenital Heart Disease." Chest. 2020;158(3):1208-1217. PMCID: PMC7478226  PMID: 32222588
Alkhatib NS, Ramos K, Erstad B, et al. "Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing." J Med Econ. 2020;23(11):1223-1229. PMID: 32845201
Kim H-J, Jung S-O, Kim H, Abraham I. "Systematic review of longitudinal studies on chemotherapy-associated subjective cognitive impairment in cancer patients." Psychooncology. 2020;29(4):617-631. PMID: 32017297
Nguyen L, Zhang X, Roberts E, et al. "Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated versus acute myeloid leukemia with myelodysplasia-related changes with mutated ." Leuk Lymphoma. 2020;61(6):1395-1405. PMCID: PMC7269833  PMID: 32091281